Loading stock data…
GHRS
$20.35+0.23 (+1.14%)
After Hours$20.75+0.40 (+1.97%)· Last close Jun 9
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GH Research PLC in the Healthcare sector is trading at $20.35 with a market capitalization of $1.7B. Wall Street consensus targets $39.50 (8 analysts), implying a +94.1% move over the next 12 months. The stock is currently 22% below its 52-week high of $25.94, remaining 29.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +94.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$20.35
Potential Downside
0%
Whystock Fair Value$20.35
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.28
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-21.42%
Volume
Today's trading volume
257,594
Recent News
H.C. Wainwright Maintains Buy Rating on GH Research (GHRS)
GH Research PLC (NASDAQ:GHRS) is one of the 10 Stocks That Have the Potential to Rise 1000%. On May 19, 2026, H.C. Wainwright lowered the firm’s price target on GH Research PLC (NASDAQ:GHRS) to $65 from $70 and maintained a Buy rating on the shares. H.C. Wainwright cited share count dilution from the company’s April […]
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Organigram Reported its Second Quarter Fiscal 2026 Financial Results Village Farms Reported Q1 2026 Results Driven by Record International Export Sales Cronos Group Reported 2026 First Quarter Financial Results Key Takeaways; Psychedelic Sector GH Research Reported First Quarter 2026 Financial Results and Provided Business Update Definium Therapeutics Announced First Patient had […]
Assessing GH Research (GHRS) Valuation After Key Phase 2b Results And Phase 3 Trial Plans
GH Research (NasdaqGM:GHRS) has drawn fresh attention after publishing Phase 2b results for its lead depression treatment in JAMA Psychiatry, advancing Phase 1 programs and outlining a global Phase 3 plan, while reporting a sizeable cash position. See our latest analysis for GH Research. Those clinical updates and fresh financing plans sit against a share price of US$21.39, with a 30-day share price return of 20.57% and a 90-day share price return of 45.51%. The 1-year total shareholder...
FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit.
Compass Pathways, the developer of synthetic psilocybin, announced it had received a government voucher.
FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain
Shares of some psychedelic drug companies gained Friday morning after the US Food and Drug Administr